Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.

摘要: A number of meningococcal vaccines have either been recently licensed or are in late-phase clinical trials. To inform national vaccination policy, it is important to define the burden disease and potential impact any new vaccine. This study describes epidemiology invasive across all age groups England Wales for recent epidemiological years between 2006 2010. The Health Protection Agency (HPA) conducts enhanced surveillance through a combination laboratory reporting. Between 2006/07 2010/11, average annual incidence was 2.0/100,000. Capsular group B (MenB) accounted 87% (4777/5471) cases, with an overall 1.8/100,000. highest MenB observed among infants (36.2/100,000) where cases increased from birth 5 months then gradually declined. An 245 occurred (135 those aged ≤ 6 months) representing 26% (and 14%) respectively. After infancy, rates declined until 12 years, rising second smaller peak at 18 years. case fatality ratio (CFR) 5.2% (247/4777 cases) ≥ 65 year-olds (28/161; 17.4%). largest deaths (n=125), however, <5 year-olds. Clonal complexes cc269 cc41/44 each around third groups. Other capsular rarely caused disease, although Y (MenY) more than doubled 35 86 2010/11. Thus, universal effective broad-spectrum formulation has prevent most particularly if vaccine immunogenic early but, there currently little justification routine quadrivalent ACWY conjugate UK, increase MenY warrants continued surveillance.